KCNH2 and colorectal carcinoma: Half of the 28 discordant drugs reviewed lacked either an in vivo QT study or hERG assay data and, of the 9 drugs submitted with the full set of nonclinical data, 3 had in vivo QTc data in which the plasma concentrations achieved were < 1-fold the CRC, whereas 2 drugs were tested only at plasma concentrations well above the clinical concentration (> 1000-fold the CRC).